/ABOS
ABOS Stock - Acumen Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$2.15+1.42%
+$0.03 (+1.42%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+225.6%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABOS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.13 – $2.17
TARGET (TP)$7.00
STOP LOSS$1.98
RISK/REWARD1:28.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.25
52W High$2.46
52W Low$0.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $1.44M |
| Gross Profit | N/A | N/A | N/A | $-12,305,000 | $-6,561,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -456.9% |
| Operating Income | $-114,017,000 | $-61,138,000 | $-45,237,000 | $-19,584,000 | $-7,912,000 |
| Net Income | $-102,329,000 | $-52,371,000 | $-42,856,000 | $-100,606,000 | $-7,325,000 |
| Net Margin | N/A | N/A | N/A | N/A | -510.1% |
| EPS | $-1.71 | $-1.08 | $-1.06 | $-2.63 | $-0.26 |
Company Overview
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 405.0% Upside
Now
$4
Low
$11
Average
$15
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 17th 2025 | Citigroup | Initiation | Buy | $4 |
| July 26th 2024 | Citigroup | Initiation | Buy | $7 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $8 |
| July 20th 2023 | BofA Securities | Resumed | Buy | $14← $9 |
| May 18th 2023 | Cantor Fitzgerald | Initiation | Overweight | $13 |
| July 15th 2022 | BTIG Research | Initiation | Buy | $15 |
| June 30th 2022 | H.C. Wainwright | Initiation | Buy | $15 |
Earnings History & Surprises
ABOSBeat Rate
39%
Last 18 quarters
Avg Surprise
-16.3%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.44
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.29vs$-0.29
Q2 24
-8.7%
$-0.25vs$-0.23
Q3 24
-21.4%
$-0.34vs$-0.28
Q4 24
-38.9%
$-0.50vs$-0.36
Q1 25
-31.9%
$-0.62vs$-0.47
Q2 25
+14.3%
$-0.48vs$-0.56
Q3 25
-25.9%
$-0.68vs$-0.54
Q4 25
+30.2%
$-0.44vs$-0.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.50 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.63 | $-0.44 | +30.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.54 | $-0.68 | -25.9% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.56 | $-0.48 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.47 | $-0.62 | -31.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.36 | $-0.50 | -38.9% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.28 | $-0.34 | -21.4% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.29 | $-0.29 | 0.0% | = MET |
Q4 2023 | Nov 13, 2023 | $-0.31 | $-0.24 | +22.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.36 | $-0.28 | +22.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.33 | $-0.28 | +15.2% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.27 | $-0.26 | +3.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.17 | $-0.23 | -35.3% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.14 | $-0.42 | -200.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.21 | $-0.10 | +52.4% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-4.56 | $-7.91 | -73.5% | ✗ MISS |
Q3 2021 | Jul 2, 2021 | — | $-0.73 | — | — |
Latest News
Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies
📈 PositiveBenzinga•Dec 2, 2025, 01:15 PM
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8
📈 PositiveBenzinga•Nov 18, 2025, 05:58 PM
Acumen Pharmaceuticals To Present Recruitment Strategies For Phase 2 ALTITUDE-AD Trial And Enhanced Brain Delivery Technology
📈 PositiveBenzinga•Nov 18, 2025, 01:07 PM
Acumen Pharmaceuticals Dosed First Patient In Phase 2 Open-Label Extension Study Of Sabirnetug In People with Early Alzheimer's.
📈 PositiveBenzinga•Nov 17, 2025, 01:13 PM
Acumen Pharmaceuticals Q3 EPS $(0.44) Beats $(0.58) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:00 PM
Acumen Pharma Appoints George Golumbeski As Chairman Of Board Of Directors
➖ NeutralBenzinga•Nov 10, 2025, 01:12 PM
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9
➖ NeutralBenzinga•Aug 25, 2025, 04:53 PM
Frequently Asked Questions about ABOS
What is ABOS's current stock price?
Acumen Pharmaceuticals, Inc. (ABOS) is currently trading at $2.15 per share. The stock has moved +1.42% today.
What is the analyst price target for ABOS?
The average analyst price target for ABOS is $7.00, based on 1 analyst.
What sector is Acumen Pharmaceuticals, Inc. in?
Acumen Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABOS's market cap?
Acumen Pharmaceuticals, Inc. has a market capitalization of $0.13 billion, making it a small-cap company.
Does ABOS pay dividends?
No, Acumen Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to ABOS for comparison